M. Curley

发表

Mammalian Target of Rapamycin Is a Therapeutic Target for Murine Ovarian Endometrioid Adenocarcinomas with Dysregulated Wnt/β-Catenin and PTEN

D. Roberts, M. Taketo, P. Tanwar, 2011, PLoS ONE.

Inhibition of Hedgehog Signaling Antagonizes Serous Ovarian Cancer Growth in a Primary Xenograft Model

Michael J. Birrer, Michael D. Curley, Jeanne A. Ferguson, 2011, PloS one.

A multicenter phase II study of istiratumab (MM-141) plus nab-paclitaxel (A) and gemcitabine (G) in metastatic pancreatic cancer (MPC).

J. A. Murray, A. Lugovskoy, M. Curley, 2016 .

Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer

B. Schoeberl, U. Nielsen, E. Pace, 2018, Clinical Cancer Research.

Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells

G. Mohapatra, B. Rueda, M. Curley, 2010, Reproductive biology and endocrinology : RB&E.

Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer.

J. Schorge, B. Rueda, M. Curley, 2011, Frontiers in bioscience.

CD133 Expression Defines a Tumor Initiating Cell Population in Primary Human Ovarian Cancer

D. Roberts, D. Scadden, B. Rueda, 2009, Stem cells.

Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121)

V. Grantcharova, B. Schoeberl, U. Nielsen, 2017, npj Systems Biology and Applications.

Epigenetic regulation of CD 133 and tumorigenicity of CD 133 positive and negative endometrial cancer cells

G. Mohapatra, B. Rueda, M. Curley, 2010 .

Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model

G. MacBeath, M. Curley, L. Wille, 2015, Molecular Cancer Therapeutics.

Seribantumab, an Anti-ERBB3 Antibody, Delays theOnsetofResistanceandRestoresSensitivityto LetrozoleinanEstrogenReceptor-PositiveBreast

G. MacBeath, M. Curley, L. Wille, 2015 .

TAK-573, an anti-CD38-targeted attenuated interferon alpha (IFNα) fusion protein, showed anti-myeloma tumor responses in combination with standard of care (SOC) agents in multiple myeloma (MM) xenograft tumor models in vivo

M. Curley, T. Taura, Mingying Bi, 2019, Clinical Lymphoma Myeloma and Leukemia.

Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer

B. Schoeberl, M. Mino‐Kenudson, A. Lugovskoy, 2019, Scientific Reports.

Abstract 1072: MM-121/SAR256212, an anti-ErbB3 antibody, restores sensitivity to letrozole and delays the onset of resistance in an ER+ breast cancer model.

G. MacBeath, M. Curley, A. Brodie, 2013 .